{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T07:12:45Z","timestamp":1771485165262,"version":"3.50.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thromboembolic events are potentially serious complications in patients undergoing bariatric surgery. Several studies have investigated the use of rivaroxaban in patients undergoing bariatric surgery. Further evidence is required to determine whether postsurgical anatomical and physiological changes affect the pharmacokinetics of rivaroxaban. This study aimed to investigate the pharmacokinetic, efficacy, and safety of rivaroxaban in patients who underwent sleeve gastrectomy surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Included patients who admitted for sleeve gastrectomy surgery and were scheduled to receive prophylactic doses of rivaroxaban. Pre- and post-operative rivaroxaban plasma concentrations were determined. Efficacy and safety were assessed 6 and 9\u00a0months after surgery. Results: Twenty patients (40% males) were included in the study. The average body weight was 117.6 \u00b1 21.2\u00a0kg. The average AUC values before, after, and 7-day after bariatric surgery were 5.83 (1.23), 5.34 (1.87), and 6.29 (2.12) \u03bcg\u00b7h mL\n                      <jats:sup>\u22121<\/jats:sup>\n                      , respectively. The average C\n                      <jats:sub>max<\/jats:sub>\n                      before, after, and 7-day after bariatric surgery were 0.45 (0.2), 0.37 (0.17), and 0.48 (0.23) \u03bcg\u00a0mL\n                      <jats:sup>\u22121<\/jats:sup>\n                      , respectively. No significant differences were observed in the rivaroxaban PK parameters. No thrombosis events were reported over 6 or 9 months. In addition, 100% of the participants experienced no significant bleeding events or other adverse effects associated with rivaroxaban during the trial period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Rivaroxaban 10\u00a0mg shows promise as a potential medication for VTE prophylaxis after bariatric surgery. However, future studies with larger, more diverse populations are needed to confirm these findings and strengthen their applicability in clinical practice and to determine the optimal dosage and long-term safety profile in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1723656","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:41:08Z","timestamp":1771483268000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of sleeve gastrectomy on rivaroxaban pharmacokinetics, efficacy, and safety"],"prefix":"10.3389","volume":"17","author":[{"given":"Saeed","family":"Alqahtani","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University","place":["Riyadh, Saudi Arabia"]},{"name":"Clinical Pharmacokinetics and Pharmacodynamics Unit, King Saud University Medical City","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anfal","family":"Almutairi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University","place":["Riyadh, Saudi Arabia"]},{"name":"Clinical Pharmacokinetics and Pharmacodynamics Unit, King Saud University Medical City","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faten","family":"Aldajani","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University","place":["Riyadh, Saudi Arabia"]},{"name":"Clinical Pharmacokinetics and Pharmacodynamics Unit, King Saud University Medical City","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manar","family":"Basudan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University","place":["Riyadh, Saudi Arabia"]},{"name":"Clinical Pharmacokinetics and Pharmacodynamics Unit, King Saud University Medical City","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arwa","family":"Alzahrani","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University","place":["Riyadh, Saudi Arabia"]},{"name":"Clinical Pharmacokinetics and Pharmacodynamics Unit, King Saud University Medical City","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Alenazi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University","place":["Riyadh, Saudi Arabia"]},{"name":"Clinical Pharmacokinetics and Pharmacodynamics Unit, King Saud University Medical City","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emad","family":"Alsarhani","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University","place":["Riyadh, Saudi Arabia"]},{"name":"Clinical Pharmacokinetics and Pharmacodynamics Unit, King Saud University Medical City","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulaziz","family":"Alsubaie","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University","place":["Riyadh, Saudi Arabia"]},{"name":"Clinical Pharmacokinetics and Pharmacodynamics Unit, King Saud University Medical City","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alhassan","family":"Almaghrabi","sequence":"additional","affiliation":[{"name":"Department of Surgery, College of Medicine, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahad","family":"Bamehriz","sequence":"additional","affiliation":[{"name":"Department of Surgery, College of Medicine, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamad","family":"Alsubaie","sequence":"additional","affiliation":[{"name":"Department of Surgery, College of Medicine, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farjah","family":"Algahtani","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.5045\/br.2020.55.1.44","article-title":"Thromboprophylaxis after bariatric surgery","volume":"55","author":"Almarshad","year":"2020","journal-title":"Blood Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/jcph.2255","article-title":"Population pharmacokinetics of rivaroxaban in real-world patients","volume":"63","author":"Alqahtani","year":"2023","journal-title":"J. Clin. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2147\/VHRM.S73799","article-title":"Prevention of venous thromboembolism in patients undergoing bariatric surgery","volume":"11","author":"Bartlett","year":"2015","journal-title":"Vasc. Health Risk Manag."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e33444","DOI":"10.7759\/cureus.33444","article-title":"Thromboembolic complications after bariatric surgery: is the high risk real?","volume":"15","author":"Carvalho","year":"2023","journal-title":"Cureus"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1381\/096089205774859245","article-title":"Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study","volume":"15","author":"Hamad","year":"2005","journal-title":"Obes. Surg."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.soard.2014.12.020","article-title":"Congestive heart failure is a risk factor for venous thromboembolism in bariatric surgery","volume":"11","author":"Haskins","year":"2015","journal-title":"Surg. Obes. Relat. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.15420\/ecr.2017:11:2","article-title":"Direct oral anticoagulants: a quick guide","volume":"12","author":"Julia","year":"2017","journal-title":"Eur. Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1111\/bcp.13243","article-title":"Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery","volume":"83","author":"Kroll","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1016\/j.soard.2018.08.025","article-title":"The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study","volume":"14","author":"Kroll","year":"2018","journal-title":"Surg. Obes. Relat. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e2315241","DOI":"10.1001\/jamanetworkopen.2023.15241","article-title":"Efficacy and safety of rivaroxaban for postoperative thromboprophylaxis in patients after bariatric surgery: a randomized clinical trial","volume":"6","author":"Kroll","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1182\/blood-2019-127645","article-title":"Efficacy and safety of direct oral factor Xa inhibitors in patients after bariatric surgery","volume":"134","author":"Kushnir","year":"2019","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.soard.2022.09.010","article-title":"Outcomes with direct-acting oral anticoagulants in patients with a history of bariatric surgery: a retrospective cohort study","volume":"19","author":"Langworthy","year":"2023","journal-title":"Surg. Obes. Relat. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1016\/j.jtha.2024.06.024","article-title":"Full-dose rivaroxaban in patients with a history of bariatric surgery: bridging the knowledge gap through a phase 1 study","volume":"22","author":"Leven","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"B14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s11239-013-0891-2","article-title":"Pharmacokinetics of rivaroxaban after bariatric surgery: a case report","volume":"36","author":"Mahlmann","year":"2013","journal-title":"J. Thromb. Thrombolysis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC subcommittee on Control of anticoagulation","volume":"19","author":"Martin","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.amjmed.2017.05.011","article-title":"Influences of obesity and bariatric surgery on the clinical and pharmacologic profile of rivaroxaban","volume":"130","author":"Moore","year":"2017","journal-title":"Am. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1381\/096089206779319383","article-title":"Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery","volume":"16","author":"Rocha","year":"2006","journal-title":"Obes. Surg."},{"key":"B19","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"B20","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/SLA.0000000000002285","article-title":"To what extent does posthospital discharge chemoprophylaxis prevent venous thromboembolism after bariatric surgery? Results from a nationwide cohort of more than 110,000 patients","volume":"267","author":"Thereaux","year":"2018","journal-title":"Ann. Surg."},{"key":"B21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/VHRM.S134394","article-title":"Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice","volume":"14","author":"Vimalesvaran","year":"2018","journal-title":"Vasc. Health Risk Manag."},{"key":"B22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.soard.2010.12.008","article-title":"Venous thromboembolism after bariatric surgery performed by bariatric surgery center of excellence participants: analysis of the bariatric outcomes longitudinal database","volume":"7","author":"Winegar","year":"2011","journal-title":"Surg. Obes. Relat. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1723656\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:41:08Z","timestamp":1771483268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1723656\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":22,"alternative-id":["10.3389\/fphar.2026.1723656"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1723656","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"article-number":"1723656"}}